Migraine Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapeutics {Pain-relieving Medications (Analgesics, Triptans, Ergot Alkaloids, Others), and Preventive Medications (Blood pressure-lowering Medications, Anticonvulsant Drugs, Calcitonin Gene-related Peptide (CGRP) Antagonists, Other Preventative Therapies)}, By Route of Administration (Oral & Nasal v/s Injectables), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Others), By Region & Competition, 2021-2031F
The Global Migraine Therapeutics Market is projected to grow from USD 4.31 Billion in 2025 to USD 5.75 Billion by 2031, achieving a CAGR of 4.92%. This market, which involves pharmacological treatments to halt acute migraine attacks or lessen the frequency and intensity of chronic episodes, is significantly bolstered by the increasing prevalence of neurological conditions. Key drivers include the introduction of targeted therapies, especially calcitonin gene-related peptide (CGRP) antagonists, which address critical unmet medical needs, alongside improved diagnostic capabilities and growing patient advocacy. These factors are shifting demand from traditional pain management towards more disease-modifying strategies. However, market expansion faces challenges from the high costs of novel biologic agents and restrictive reimbursement policies. According to The Migraine Trust, 92% of participants in a 2025 survey reported that migraines impacted their work ability, underscoring the substantial economic burden and the urgent need for effective clinical management.
Market Driver
The market is primarily driven by the rapid adoption of CGRP inhibitors and gepants, which are transforming the therapeutic landscape by offering precise, mechanism-based treatments superior to traditional triptans. These drugs, designed to block the migraine-associated calcitonin gene-related peptide, have gained significant commercial traction, being approved for both acute and preventive treatment. Evidence of their success is seen in AbbVie's October 2025 financial disclosures, reporting a 64.1% increase in Qulipta's global net revenues to $288 million, indicating a shift towards disease-specific interventions. Furthermore, the increasing global prevalence of migraine and headache disorders acts as a major volume driver, creating a vast patient pool requiring long-term management. With an estimated 1.16 billion prevalent migraine cases globally by November 2025 (Frontiers), the condition imposes a substantial financial strain, with the Headache and Migraine Policy Forum reporting $78 billion in lost productivity and healthcare costs annually in the U.S. This growing incidence and economic burden ensure sustained demand for advanced pharmacotherapy.
Market Challenge
The primary obstacle to growth in the Global Migraine Therapeutics Market is the prohibitive cost of innovative biologic agents, which has prompted healthcare payers to implement restrictive reimbursement policies. Although targeted therapies like CGRP antagonists address significant unmet needs, their premium pricing leads to rigorous utilization management strategies such as prior authorization and step therapy, designed to control expenditure. These complex access barriers oblige pharmaceutical companies to navigate a market where clinical efficacy doesn't guarantee broad access, significantly impeding the commercial adoption of these specialized medications and hindering the market's ability to capitalize on the rising prevalence of neurological conditions. Such reimbursement hurdles directly reduce prescription volumes and consequently stall manufacturers' revenue growth. The Headache and Migraine Policy Forum reported in 2024 that 93% of patients faced step therapy requirements before their prescribed treatment was approved, demonstrating how these administrative restrictions delay essential care and discourage adherence to advanced treatment plans, thereby limiting market expansion despite strong patient demand.
Market Trends
Current market trends include the expansion of regulatory approvals and label indications for pediatric use, which formally extends access to advanced biologics for younger patients who previously relied on off-label generics. Pharmaceutical companies are actively seeking label extensions for CGRP inhibitors to address the considerable unmet needs in adolescents, moving beyond an adult-focused revenue model. A key example is Teva Pharmaceuticals' August 2025 FDA approval for AJOVY in patients aged 6 to 17, based on Phase 3 trial data showing a statistically significant reduction of 2.5 monthly migraine days. Concurrently, the integration of Prescription Digital Therapeutics (PDTs) and wearables is establishing a complementary non-pharmacological treatment vertical. Manufacturers are successfully securing commercial payer coverage for remote electrical neuromodulation devices by demonstrating real-world efficacy and cost-effectiveness. This allows for hybrid treatment protocols where digital interventions can mitigate the side effects associated with heavy medication regimens, positioning these technologies as standard-of-care options, as exemplified by Theranica's Nerivio gaining coverage for an additional 3.4 million lives by December 2025.
Key Market Players
In this report, the Global Migraine Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Migraine Therapeutics Market.
Available Customizations:
Global Migraine Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Market Driver
The market is primarily driven by the rapid adoption of CGRP inhibitors and gepants, which are transforming the therapeutic landscape by offering precise, mechanism-based treatments superior to traditional triptans. These drugs, designed to block the migraine-associated calcitonin gene-related peptide, have gained significant commercial traction, being approved for both acute and preventive treatment. Evidence of their success is seen in AbbVie's October 2025 financial disclosures, reporting a 64.1% increase in Qulipta's global net revenues to $288 million, indicating a shift towards disease-specific interventions. Furthermore, the increasing global prevalence of migraine and headache disorders acts as a major volume driver, creating a vast patient pool requiring long-term management. With an estimated 1.16 billion prevalent migraine cases globally by November 2025 (Frontiers), the condition imposes a substantial financial strain, with the Headache and Migraine Policy Forum reporting $78 billion in lost productivity and healthcare costs annually in the U.S. This growing incidence and economic burden ensure sustained demand for advanced pharmacotherapy.
Market Challenge
The primary obstacle to growth in the Global Migraine Therapeutics Market is the prohibitive cost of innovative biologic agents, which has prompted healthcare payers to implement restrictive reimbursement policies. Although targeted therapies like CGRP antagonists address significant unmet needs, their premium pricing leads to rigorous utilization management strategies such as prior authorization and step therapy, designed to control expenditure. These complex access barriers oblige pharmaceutical companies to navigate a market where clinical efficacy doesn't guarantee broad access, significantly impeding the commercial adoption of these specialized medications and hindering the market's ability to capitalize on the rising prevalence of neurological conditions. Such reimbursement hurdles directly reduce prescription volumes and consequently stall manufacturers' revenue growth. The Headache and Migraine Policy Forum reported in 2024 that 93% of patients faced step therapy requirements before their prescribed treatment was approved, demonstrating how these administrative restrictions delay essential care and discourage adherence to advanced treatment plans, thereby limiting market expansion despite strong patient demand.
Market Trends
Current market trends include the expansion of regulatory approvals and label indications for pediatric use, which formally extends access to advanced biologics for younger patients who previously relied on off-label generics. Pharmaceutical companies are actively seeking label extensions for CGRP inhibitors to address the considerable unmet needs in adolescents, moving beyond an adult-focused revenue model. A key example is Teva Pharmaceuticals' August 2025 FDA approval for AJOVY in patients aged 6 to 17, based on Phase 3 trial data showing a statistically significant reduction of 2.5 monthly migraine days. Concurrently, the integration of Prescription Digital Therapeutics (PDTs) and wearables is establishing a complementary non-pharmacological treatment vertical. Manufacturers are successfully securing commercial payer coverage for remote electrical neuromodulation devices by demonstrating real-world efficacy and cost-effectiveness. This allows for hybrid treatment protocols where digital interventions can mitigate the side effects associated with heavy medication regimens, positioning these technologies as standard-of-care options, as exemplified by Theranica's Nerivio gaining coverage for an additional 3.4 million lives by December 2025.
Key Market Players
- Amgen Inc.
- Teva Pharmaceutical Industries Limited
- GlaxoSmithKline plc
- Eli Lilly and Company
- Bausch Health Companies Inc.
- Novartis AG
- AbbVie Inc.
- Lundbeck Inc
- Dr. Reddy's Laboratories Limited
- Impel Pharmaceuticals Inc
In this report, the Global Migraine Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Migraine Therapeutics Market, By Therapeutics
- Pain-relieving Medications
- Preventive Medications
- Migraine Therapeutics Market, By Route of Administration
- Oral & Nasal
- Injectables
- Migraine Therapeutics Market, By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Others
- Migraine Therapeutics Market, By Region
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Migraine Therapeutics Market.
Available Customizations:
Global Migraine Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL MIGRAINE THERAPEUTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Therapeutics {Pain-relieving Medications (Analgesics, Triptans, Ergot Alkaloids, Others), and Preventive Medications (Blood pressure-lowering Medications, Anticonvulsant Drugs, Calcitonin Gene-related Peptide (CGRP) Antagonists, Other Preventative Therapies)}
5.2.2. By Route of Administration (Oral & Nasal v/s Injectables)
5.2.3. By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Others)
5.2.4. By Region
5.2.5. By Company (2025)
5.3. Market Map
6. NORTH AMERICA MIGRAINE THERAPEUTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Therapeutics
6.2.2. By Route of Administration
6.2.3. By Distribution Channel
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Migraine Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Therapeutics
6.3.1.2.2. By Route of Administration
6.3.1.2.3. By Distribution Channel
6.3.2. Canada Migraine Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Therapeutics
6.3.2.2.2. By Route of Administration
6.3.2.2.3. By Distribution Channel
6.3.3. Mexico Migraine Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Therapeutics
6.3.3.2.2. By Route of Administration
6.3.3.2.3. By Distribution Channel
7. EUROPE MIGRAINE THERAPEUTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Therapeutics
7.2.2. By Route of Administration
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Migraine Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Therapeutics
7.3.1.2.2. By Route of Administration
7.3.1.2.3. By Distribution Channel
7.3.2. France Migraine Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Therapeutics
7.3.2.2.2. By Route of Administration
7.3.2.2.3. By Distribution Channel
7.3.3. United Kingdom Migraine Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Therapeutics
7.3.3.2.2. By Route of Administration
7.3.3.2.3. By Distribution Channel
7.3.4. Italy Migraine Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Therapeutics
7.3.4.2.2. By Route of Administration
7.3.4.2.3. By Distribution Channel
7.3.5. Spain Migraine Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Therapeutics
7.3.5.2.2. By Route of Administration
7.3.5.2.3. By Distribution Channel
8. ASIA PACIFIC MIGRAINE THERAPEUTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Therapeutics
8.2.2. By Route of Administration
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Migraine Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Therapeutics
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By Distribution Channel
8.3.2. India Migraine Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Therapeutics
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By Distribution Channel
8.3.3. Japan Migraine Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Therapeutics
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By Distribution Channel
8.3.4. South Korea Migraine Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Therapeutics
8.3.4.2.2. By Route of Administration
8.3.4.2.3. By Distribution Channel
8.3.5. Australia Migraine Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Therapeutics
8.3.5.2.2. By Route of Administration
8.3.5.2.3. By Distribution Channel
9. MIDDLE EAST & AFRICA MIGRAINE THERAPEUTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Therapeutics
9.2.2. By Route of Administration
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Migraine Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Therapeutics
9.3.1.2.2. By Route of Administration
9.3.1.2.3. By Distribution Channel
9.3.2. UAE Migraine Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Therapeutics
9.3.2.2.2. By Route of Administration
9.3.2.2.3. By Distribution Channel
9.3.3. South Africa Migraine Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Therapeutics
9.3.3.2.2. By Route of Administration
9.3.3.2.3. By Distribution Channel
10. SOUTH AMERICA MIGRAINE THERAPEUTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Therapeutics
10.2.2. By Route of Administration
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Migraine Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Therapeutics
10.3.1.2.2. By Route of Administration
10.3.1.2.3. By Distribution Channel
10.3.2. Colombia Migraine Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Therapeutics
10.3.2.2.2. By Route of Administration
10.3.2.2.3. By Distribution Channel
10.3.3. Argentina Migraine Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Therapeutics
10.3.3.2.2. By Route of Administration
10.3.3.2.3. By Distribution Channel
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL MIGRAINE THERAPEUTICS MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Amgen Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Teva Pharmaceutical Industries Limited
15.3. GlaxoSmithKline plc
15.4. Eli Lilly and Company
15.5. Bausch Health Companies Inc.
15.6. Novartis AG
15.7. AbbVie Inc.
15.8. Lundbeck Inc
15.9. Dr. Reddy's Laboratories Limited
15.10. Impel Pharmaceuticals Inc
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL MIGRAINE THERAPEUTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Therapeutics {Pain-relieving Medications (Analgesics, Triptans, Ergot Alkaloids, Others), and Preventive Medications (Blood pressure-lowering Medications, Anticonvulsant Drugs, Calcitonin Gene-related Peptide (CGRP) Antagonists, Other Preventative Therapies)}
5.2.2. By Route of Administration (Oral & Nasal v/s Injectables)
5.2.3. By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Others)
5.2.4. By Region
5.2.5. By Company (2025)
5.3. Market Map
6. NORTH AMERICA MIGRAINE THERAPEUTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Therapeutics
6.2.2. By Route of Administration
6.2.3. By Distribution Channel
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Migraine Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Therapeutics
6.3.1.2.2. By Route of Administration
6.3.1.2.3. By Distribution Channel
6.3.2. Canada Migraine Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Therapeutics
6.3.2.2.2. By Route of Administration
6.3.2.2.3. By Distribution Channel
6.3.3. Mexico Migraine Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Therapeutics
6.3.3.2.2. By Route of Administration
6.3.3.2.3. By Distribution Channel
7. EUROPE MIGRAINE THERAPEUTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Therapeutics
7.2.2. By Route of Administration
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Migraine Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Therapeutics
7.3.1.2.2. By Route of Administration
7.3.1.2.3. By Distribution Channel
7.3.2. France Migraine Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Therapeutics
7.3.2.2.2. By Route of Administration
7.3.2.2.3. By Distribution Channel
7.3.3. United Kingdom Migraine Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Therapeutics
7.3.3.2.2. By Route of Administration
7.3.3.2.3. By Distribution Channel
7.3.4. Italy Migraine Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Therapeutics
7.3.4.2.2. By Route of Administration
7.3.4.2.3. By Distribution Channel
7.3.5. Spain Migraine Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Therapeutics
7.3.5.2.2. By Route of Administration
7.3.5.2.3. By Distribution Channel
8. ASIA PACIFIC MIGRAINE THERAPEUTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Therapeutics
8.2.2. By Route of Administration
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Migraine Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Therapeutics
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By Distribution Channel
8.3.2. India Migraine Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Therapeutics
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By Distribution Channel
8.3.3. Japan Migraine Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Therapeutics
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By Distribution Channel
8.3.4. South Korea Migraine Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Therapeutics
8.3.4.2.2. By Route of Administration
8.3.4.2.3. By Distribution Channel
8.3.5. Australia Migraine Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Therapeutics
8.3.5.2.2. By Route of Administration
8.3.5.2.3. By Distribution Channel
9. MIDDLE EAST & AFRICA MIGRAINE THERAPEUTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Therapeutics
9.2.2. By Route of Administration
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Migraine Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Therapeutics
9.3.1.2.2. By Route of Administration
9.3.1.2.3. By Distribution Channel
9.3.2. UAE Migraine Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Therapeutics
9.3.2.2.2. By Route of Administration
9.3.2.2.3. By Distribution Channel
9.3.3. South Africa Migraine Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Therapeutics
9.3.3.2.2. By Route of Administration
9.3.3.2.3. By Distribution Channel
10. SOUTH AMERICA MIGRAINE THERAPEUTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Therapeutics
10.2.2. By Route of Administration
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Migraine Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Therapeutics
10.3.1.2.2. By Route of Administration
10.3.1.2.3. By Distribution Channel
10.3.2. Colombia Migraine Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Therapeutics
10.3.2.2.2. By Route of Administration
10.3.2.2.3. By Distribution Channel
10.3.3. Argentina Migraine Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Therapeutics
10.3.3.2.2. By Route of Administration
10.3.3.2.3. By Distribution Channel
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL MIGRAINE THERAPEUTICS MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Amgen Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Teva Pharmaceutical Industries Limited
15.3. GlaxoSmithKline plc
15.4. Eli Lilly and Company
15.5. Bausch Health Companies Inc.
15.6. Novartis AG
15.7. AbbVie Inc.
15.8. Lundbeck Inc
15.9. Dr. Reddy's Laboratories Limited
15.10. Impel Pharmaceuticals Inc
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
